New generation antipsychotic drugs and compliance behaviour

Current Opinion in Psychiatry

Volumn 21, Issue 2, 2008, Pages 133-139

  Voruganti, Lakshmi P ^a,c   Baker, Laura K ^a   Awad, A George ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c NONE   (Canada)

Author keywords

Antipsychotics; Compliance; Persistence; Schizophrenia; Treatment adherence

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

CLINICAL TRIAL; DATA BASE; DRUG EFFICACY; DRUG WITHDRAWAL; HEALTH CARE; HEALTH CARE PERSONNEL; HUMAN; MEDICAL LITERATURE; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; HUMANS; PATIENT COMPLIANCE; SCHIZOPHRENIA;

EID: 40349110748     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/YCO.0b013e3282f52851     Document Type: Review

References (58)

1. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002; 40:794-811.
2. Osterberg L, Blaschke T. Drug therapy: adherence to medication. N Engl J Med 2005; 353:487-497.
3. McEvoy JP, Howe AC, Hogarty GE. Differences in the nature of relapse and subsequent inpatient course between medication-compliant and noncompliant schizophrenic patients. J Nerv Ment Dis 1984; 172:412-416.
4. Velligan DI, Lam YF, Glahn DC, et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull 2006; 32:724-742. Provides an excellent overview of the subject based on a literature review as well as the authors' own studies and experience over the years.
5. Sackett DL, Haynes RB. Compliance with therapeutic regimens. Baltimore, MD: Johns Hopkins University Press; 1976.
6. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: terminology and definitions. Value Health (in press).
7. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records: description and validation. Med Care 1988; 26:814-823.
8. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002; 40:630-639.
9. Hamilton RA, Briceland LL. Use of prescription-refill records to assess patient compliance. Am J Hosp Pharm 1992; 49:1691-1696.
10. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997; 50:105-116.
11. Thompson K, Kulkarni J, Sergejew AA. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 2000; 42:241-247.
12. Kemp R, David A. Psychological predictors of insight and compliance in psychotic patients. Br J Psychiatry 1996; 169:444-450.
13. Weiden P, Rapkin B, Mott T, et al. Rating of Medication Influences (ROMI) scale in schizophrenia. Schizophr Bull 1994; 20:297-310.
14. Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993; 19:609-618.
15. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995; 10 (Suppl 3):133-138.
16. Voruganti LN, Awad AG. Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res 2002; 56:37-46.
17. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991; 17:325-351.
18. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Washington, DC: American Psychiatric Press; 2004.
19. Nose M, Barbui C, Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychol Med 2003; 33:1149-1160.
20. Hogarty GE. Medication adherence studies in schizophrenia. Am J Psychiatry 2004; 161:581-582.
21. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002; 106:286-290.
22. Hawton K, Sutton L, Haw C, et al. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 2005; 187:9-20.
23. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002; 63:892-909.
24. Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. J Clin Psychiatry 1996; 57 (Suppl 11):68-71.
25. Voruganti L, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology (Berl) 2004; 171:121-131.
26. Simpson GM. Atypical antipsychotics and the burden of disease. Am J Manag Care 2005; 11:S235-S241.
27. Awad AG, Voruganti L. Impact of novel antipsychotic drugs. CNS Drugs 2004; 18:877-893.
28. Mortimer AM, Al-Agib AO. Quality of life in schizophrenia on conventional versus atypical antipsychotic medication: a comparative cross-sectional study. Int J Soc Psychiatry 2007; 53:99-107.
29. Perkins DO, Johnson JL, Hamer RM, et al., HGDH Research Group. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res 2006; 83:53-63. The study was driven by sound theory and excellent methodological rigour. Evaluating the relevance of a health beliefs model in understanding compliance represents a significant step.
30. Nakonezny PA, Byerly MJ. Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first- vs second-generation antipsychotics. Schizophr Res 2006; 82:107-114.
31. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223.
32. Stroup TS, McEvoy JP, Swartz MS, et al. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr Bull 2003; 29:15-31.
33. Silva de Lima M, de Jesus Mari J, Breier A, et al. Quality of life in schizophrenia: a multicenter, randomized, naturalistic, controlled trial comparing olanzapine to first-generation antipsychotics. J Clin Psychiatry 2005; 66:831-838.
34. Haro JM, Edgell ET, Novick D, et al. SOHO Advisory Board. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005; 111:220-231.
35. Diaz E, Neuse E, Sullivan MC, et al. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiatry 2004; 65:354-360.
36. Csernansky JG, Mahmoud R, Brenner R, Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346:16-22.
37. Dolder CR, Lacro JP, Dunn LB, Jeste DV. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159:103-108.
38. Al-Zakwani IS, Barron JJ, Bullano MF, et al. Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications. Curr Med Res Opin 2003; 19:619-626.
39. Gibson PJ, Damler R, Jackson EA, et al. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a medicaid population. Value Health 2004; 7:22-35.
40. Eaddy M, Grogg A, Locklear J. Assessment of compliance with antipsychotic treatment and resource utilization in a Medicaid population. Clin Ther 2005; 27:263-272.
41. Ren XS, Qian S, Lee AF, et al. Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents. J Clin Pharm Ther 2006; 31:57-65.
42. Gianfrancesco FD, Rajagopalan K, Sajatovic M, Wang RH. Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics. Psychiatry Res 2006; 144:177-189.
43. Cooper D, Moisan J, Gregoire JP. Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia. J Clin Psychiatry 2007; 68:818-825. An unbiased, database study that involved a fair sized sample and various new antipsychotic drugs. Also showed that suboptimal doses tend to affect compliance, and possibly clinical outcomes.
44. Vanelli M, Burstein P, Cramer J. Refill patterns of atypical and conventional antipsychotic medications at a national retail pharmacy chain. Psychiatr Serv 2001; 52:1248-1250.
45. Menzin J, Boulanger L, Friedman M, et al. Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program. Psychiatr Serv 2003; 54:719-723.
46. Rijcken CA, Tobi H, Vergouwen AC, de Jong-van den Berg LT. Refill rate of antipsychotic drugs: an easy and inexpensive method to monitor patients' compliance by using computerized pharmacy data. Pharmacoepidemiol Drug Saf 2004; 13:365-370.
47. Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004; 30:255-264.
48. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and healthcare costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004; 161:692-699.
49. Van Putten T, Marder SR. Behavioral toxicity of antipsychotic drugs. J Clin Psychiatry 1987; 48 (Suppl):13-19.
50. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983; 13:177-183.
51. Löffler W, Kilian R, Toumi M, Angermeyer MC. Schizophrenic patients' subjective reasons for compliance and noncompliance with neuroleptic treatment. Pharmacopsychiatry 2003; 36:105-112.
52. Naber D, Karow A, Lambert M. Subjective well being under the neuroleptic treatment and its relevance for compliance. Acta Psychiatr Scand Suppl 2005; 427:29-34.
53. Voruganti L, Cortese L, Owyeumi L, et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 2002; 57:201-208.
54. Cabeza IG, Amador MS, Lopez CA, Chavex MG. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr Res 2000; 41:349-355.
55. Swanson JW, Swartz MS, Elbogen EB. Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophr Bull 2004; 30:3-20.
56. Velligan DI, Lam F, Ereshefsky L, et al. Psychopharmacology: perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv 2003; 54:665-667.
57. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S. Dropout rates in randomised antipsychotic trials. Psychopharmacology 2001; 155:230-233.
58. Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007; 115:260-267.